Starting in 2027, the controversial drug middlemen will have to share a broad swath of fee and compensation data with their self-funded employer clients. Employers cheered the rule, while PBMs slammed it as government overreach.
Starting in 2027, the controversial drug middlemen will have to share a broad swath of fee and compensation data with their self-funded employer clients. Employers cheered the rule, while PBMs slammed it as government overreach.